May 6, 2015

Annual and Special Meeting of the Shareholders

Germain Carrière Chairman of the Board

2

Agenda of the Meeting • Order of the day • Appointment of secretary and scrutineer • Verification of the validity of the Meeting

• Conformity of deadline of Notice • Quorum

• General Meeting • Financial Results for the period ended December 31, 2014,

by Benoît Deschamps, CFO • Appointment of Directors • Appointment of the Independent Auditors • Shareholders Rights Plan • Stock Option Plan • Other • Review of Business, by R.M. (Ric) Rumble, CEO

3

May 6, 2015

Annual and Special Meeting of the Shareholders

Benoît Deschamps Chief Financial Officer

Financial Results - Period ended December 31, 2014

5

Financial Highlights - Fiscal year 2014

6

FISCAL YEARS

ENDED DECEMBER 31 (In thousands of $, except for per share data) 2014 2013

$ $

Revenue 433 254 Net Loss, as Reported 5,948 9,270

Adjustments for non-recurrent items R&D Tax Credits (570) (289) Write-off of assets related to the old ozone-only sterilizer 294 -

Settlement Cost - 1,864 Adjusted Net Loss 6,224 7,695 Net Loss per Share, as Reported 0.08 0.13 Net Loss per Share, as Adjusted 0.09 0.11 Average Monthly Cash Burn Rate, as Adjusted for Non-Recurrent Items (460) (626)

Highlights - Q1 2015

7

FIRST QUARTER

(In thousands of $, except for per share data) 2015 2014 ACTUAL ACTUAL

Revenue 90 82 Net Loss, as Reported (1,818) (1,561)

Adjustments for non-recurrent items Write-off of Patents 214 R&D Tax Credits (35) (255) Net Adjusted Loss (1,638) (1,816) Net Loss per Share, as Reported 0.02 0.02 Net Loss per Share, as Adjusted 0.02 0.02 Average Monthly Cash Burn Rate, as Adjusted for Non-Recurrent Items (452) (550)

Retrospective since 2008

8

9

Expenses Retrospective

(2,000,000)

-

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

14,000,000

2008 2009 2010 2011 2012 2013 2014

Contract Termination Cost

Financial Expenses

Administration

Marketing, Sale and Service

Supply Chain

Research and Development

R&D Tax Credits

Financial Revenues

10

Revenue and Loss History

(12,000,000)

(10,000,000)

(8,000,000)

(6,000,000)

(4,000,000)

(2,000,000)

-

2,000,000

4,000,000

6,000,000

2008 2009 2010 2011 2012 2013 2014License Revenue

Sale of goods andservices

Loss

Cash Burn Rate 11

0100200300400500600700800900

1,000

Q1-

2010

Q2-

2010

Q3-

2010

Q4-

2010

Q1-

2011

Q2-

2011

Q3-

2011

Q4-

2011

Q1-

2012

Q2-

2012

Q3-

2012

Q4-

2012

Q1-

2013

Q2-

2013

Q3-

2013

Q4-

2013

Q1-

2014

Q2-

2014

Q3-

2014

Q4-

2014

Q1-

2015

Average Burn RateAdjusted for R&D Tax Credits and One-Line Items

(in Thousands of $)

Build up of working capital

Recovery of working capital

Q1-2011 to Q1-2012 – Burn rate of $734,000

Last 12 months: Burn rate of

$436,000

36 months from Q1-2011 to Q4-2013

How Long Will the Liquidities Last?

12

(2,000)

-

2,000

4,000

6,000

8,000

10,000

12,000

14,000

16,000

LTM Burn Rate (Q2-2014 to Q1-2015)

36 months from Q1-2011 to Q4-2013

15 months from Q1-2011 to Q1-2012

0.00 $

0.50 $

1.00 $

1.50 $

2.00 $

2.50 $se

pt. 2

008

janv.

2009

mai 2

009

sept

. 200

9

janv.

2010

mai 2

010

sept

. 201

0

janv.

2011

mai 2

011

sept

. 201

1

janv.

2012

mai 2

012

sept

. 201

2

janv.

2013

mai 2

013

sept

. 201

3

janv.

2014

mai 2

014

sept

. 201

4

janv.

2015

TSO3 Closing Stock Price

2009-09-02 LOI with 3M

2009-12-29 FDA Filing and CE Mark

TSO3 Closing Stock Price 13

2010-06-09 NSE Letter

2011-06-30 Re-Submission with FDA

2012-08-02 Termination of 3M Agreement announced

2013-01-28 Clean-up 510(k) file submitted

2014-12-17 Clearance announced

Agenda of the Meeting • Order of the day • Appointment of secretary and scrutineer • Verification of the validity of the Meeting

• Conformity of deadline of Notice • Quorum

• General Meeting • Financial Results for the period ended December 31, 2014,

by Benoît Deschamps, CFO • Appointment of Directors • Appointment of the Independent Auditors • Shareholders Rights Plan • Stock Option Plan • Other • Review of Business, by R.M. (Ric) Rumble, CEO

14

Appointment of Directors

15

Appointment of Independent Auditors

16

Me Claude Lacroix Shareholders Rights Plan

17

Article 6.5 a)(version anglaise seulement)

18

6.5 SUPPLEMENTS AND AMENDMENTS (a) The Company may make amendments to this Agreement from time to time to correct any clerical or typographical error or which are required to maintain the validity of this Agreement as a result of any change in any applicable legislation, rules or regulations or decision of a court or regulatory authority. The Company, at or prior to the meeting of shareholders of the Company referred to in section 6.16, may supplement or amend this Agreement without the approval of any holders of Rights or Voting Shares where the Board of Directors considers such action to be necessary or desirable (whether or not such action would materially adversely affect the interests of the holders of Rights generally).

Stock Option Plan

19

Stock Option Plan

The amendment is sought:

To consider and to approve an ordinary resolution approving the replenishment of the number of common shares reserved under the Stock Option Plan by a number equal to the common shares that have been issued following the exercice of options under the Stock Option Plan and to increase of the number of common shares reserved for issuance by 2,670,427 common shares so the total number of common shares reserved for issuance of options be fixed at 8,200,000 shares.

20

Agenda of the Meeting • Order of the day • Appointment of secretary and scrutineer • Verification of the validity of the Meeting

• Conformity of deadline of Notice • Quorum

• General Meeting • Financial Results for the period ended December 31, 2014,

by Benoît Deschamps, CFO • Appointment of Directors • Appointment of the Independent Auditors • Shareholders Rights Plan • Stock Option Plan • Other • Review of Business, by R.M. (Ric) Rumble, CEO

21

May 6, 2015

Annual and Special Meeting of the Shareholders

R.M. (Ric) Rumble President and Chief Executive Officer

23

23

Forward-looking Information

24

The speeches made during this meeting may include forward-looking information with

respect to the Company, including its business operations, strategy, financial

performance and condition. Although management of the Corporation believes that the

conclusions, estimates or projections reflected in such forward-looking information are

reasonable and represent the Company’s conclusions, estimates or projections at this

time, such information involves unknown risks and uncertainties which may cause the

Company’s actual results to differ materially from the Company’s conclusions,

estimates or projections expressed or implied by such forward-looking information. The

listener is cautioned not to place undue reliance on these forward-looking statements.

We do not undertake to update any forward-looking statement that is contained in the

MD&A or mentioned during this meeting.

24

Our Vision

25

“To Create the Improved Standard in Healthcare Sterile ReprocessingTM”

Company Overview

• Founded in 1998 • Designs and Manufactures Low Temperature Sterilizers

for Medical Devices • IPO 2001 • TSX: TOS • Outstanding Shares: 82.6 M ---------------------------------------------------------------------------------------------------------------------------------------------------------

• FDA 510(k) Cleared – December 2014 • Financing Completed – March 5, 2015 • Distribution Agreement Signed: – GETINGE Infection Control – March, 2015

26

What We Do

TSO3 Low Temperature Sterilization Systems offer:

Reliability Low cost Rapid turnaround Compatibility Environmentally Friendly Efficiency High Volume

Solutions for simple and complex reusable medical devices that cannot withstand other harsh sterilization modalities

27

Reprocessing Areas in Hospitals 28

CSSD - STERILE GI – High Level Disinfected

Why Low Temperature Sterilization? (market drivers)

29

Market Drivers 30

2001 2005 2010 2015 2020

65 yrs +

45 to 64

15 to 44

- 15 yrs

Aging Population

53% Increase

Age Impact on Demand and Type of Surgery

45 55 65 75

Percentage of procedures (average)

by age

88% of ophthalmology surgeries

70% of cardiothoracic surgeries

65% of urology surgeries

60% of general surgeries

31

45 55 65 75

Open Surgery Minimally Invasive Surgery (MIS)

MIS Procedures 32

MIS

Cardiology

Gastrointestinal Urology

Gynaecology

Pulmonary medicine

Neurosurgery

30 million + surgeries in US/year

Orthopaedic

Increasingly used and finding new applications everyday

MIS Devices Complex and Delicate

MIS Devices

Require Low Temperature Sterilization

33

Global Market Overview / Low Temperature Sterilization

34

Capital Equipment Business

– Low Temperature Gas Sterilizers in Hospitals:

• ~30,000 installed worldwide

• Life span ~ 10 years

• Replacement business: 3,000 units/year

Total Replacement Value $4.5bln

USCanadaEuropeROW

Consumables

- Accelerating revenus due to increased placements and increased daily cycles

Worldwide Installed Base

Frost & Sullivan 2005 and TSO3 estimates

Growth Market

35

• 2013-2019: from $5.13bln to $9.15bln; (CAGR @ 8.5%)

Sterilization and

Disinfection Devices

• Projected at 10.9% CAGR during the forecasted period

Low Temperature Sterilization –

Fastest Growth

Segment

Source: Transparency Market Research 2013

Regulatory: Cleared Territories STERIZONE® 125L+ Sterilizer and Accessories

• Canada • Europe • Selected APAC Countries

STERIZONE® VP4 Sterilizer with Accessories

• USA

36

US Regulatory Clearance Update

STERIZONE® STERILIZATION SYSTEM

• The STERIZONE® VP4 Sterilizer (K14163)

• The STERIZONE® BI+ Biological Indicator and STERIZONE® VP4 Test Pack (K141580)

• The STERIZONE® CI+ Chemical Indicator (K141698)

37

December 17, 2014 - CLEARED

Creation of a New Product Code 38

• Ethylene Oxide Gas Sterilizer Points to pre-1976 marketed device

Regulation Description

• Two or More Sterilant Sterilizer Device Classification Name

Newly Created Classification

Name

• PJJ New Product Code

Resulting in New Product

Code

STERIZONE® VP4 Sterilizer 39

STERIZONE® VP4 Sterilizer • Unique cycle intended for

rigid lumen, flex, and non-lumen devices

• Cycle comprises two phases including H2O2 injection, followed by O3 injection and dwell

Hydrogen Peroxide • 125-280 Solution™

bottle containing 280mL of 50% H2O2 solution

• Each phase can use between 7 and 20.1 mL of solution

Vaporizing technology

• Vaporizer temperature:

120°C • Vaporizes and injects

multiple and continuous pulses of a small quantity ~40 mg of 50 wt% H2O2 solution.

Other particularitie • 125 L (4.3 cu’) Chamber

Volume • Chamber temperature set to

41°C • Vented with medical grade

O2 • Separate loading rack (not

shown) • O3 generator providing a

mixture of O2 and O3 at a dose of 2 mg/L for residual H2O2 reduction

Cleared Claims

STERIZONE® VP4 Sterilizer

Retained ALL Claims within the file submitted and cleared in 2014!

• Broadest claims in industry; more devices and greater flexibility of load configurations

• Flexible, rigid, general instruments in the same load

• Largest quantity of devices in industry

• Highest gross weight available in a single load

- Supported by multiple validation loads

STERIZONE® BI+/ Test Pack

• “Demonstrated to be more resistant than the full half-cycle, including exposure to hydrogen peroxide and ozone”

• 18-hour incubation

• Shelf life of 12 months

40

Throughput Defined

One load vs. three… • Mixed loads • Greater quantity • Great complexity • Reduced time • Reduced cost

41

Customer Benefits

Single cycle, for all loads Ease of use / Reduction of operator error / Enhanced quality

Utilizable three shelf racks Makes the STERIZONE® VP4 Sterilizer (4.3 cu’) chamber fully usable

- Most instruments per load (Reduced operating cost/Faster turnaround)

Least load restrictions Flexible chamber content

- Efficacious throughput (Reduced time to process)

42

Efficacious, Rapid, Low Cost, Compatible, High Throughput Sterilization Process

Reprocessing Areas in Hospitals 43

CSSD - STERILE GI – High Level Disinfected

Reprocessing The What to DO ... and When ...

44

Spaulding Classification

Mar

gin

of s

afet

y

HIGHEST

LOWEST

Body Contact Disinfection Requirements

FDA Device Class

Intact skin Low level disinfection

Non-critical

Mucous membranes

High level disinfection

Semi-critical

Sterile body cavity

Sterilization Critical

Superbug

Antimicrobial resistance (AMR) occurs when a microbe acquires a genetic mutation making it resistant to the effect of one or more antimicrobial agents that were once effective (Source Wikipedia) Montreal hospital battles superbug CBC News Posted: Mar 01, 2010

Tricky new superbug making inroads in Canada; Montreal hospital battled outbreak by News Staff Posted Sep 19, 2011

TORONTO -- Outbreaks in two Toronto-area hospitals of a dangerous new form of superbug has infection control experts contemplating a worrisome future.

“…some CRE bacteria have become resistant to most available antibiotics. Infections with these germs are very difficult to treat, and can be deadly—one report cites they can contribute to death in up to 50% of patients who become infected.”

Centers for Disease Control (CDC) Warns CRE Infections More Common, More Resistant; Its findings, published in Vital Signs, call on states, communities, medical facility CEOs, health care providers, and patients to take steps to prevent serious infections.

CRE bacteria linked to seven infections, 2 deaths at UCLA; Posted by Staff on February 19, 2015

45

Increased Importance of Technology

46

Diagnostic instruments (mucous membranes) are being repurposed for use in surgical (sterile body cavity) procedures

High Level Disinfection STERILIZATION…?

Endoscopic Retrograde Cholangiopancreatography (ERCP)

Opportunity Expansion Our Data The STERIZONE® VP4 Sterilizer offers a single cycle

• Current dimensional limits in the USA are:

• 1 mm diameter by 850 mm x 3 per cycle

In Canada the STERIZONE® 125L+ Sterilizer, Cycle “3” is cleared for extended claims:

• 1 mm diameter by >3,000 mm x 24 channels per cycle

Scopes in the “News” have the following approximate dimensions:

• 4 mm by 1.25 m

TSO3 in-house data supports feasibility of pursuing enhanced claim to existing

clearance (not a new clearance) for high risk flexible endoscopes

47

Potential “ERCP” Opportunity

Sterilization as a standard of practice ... IMPACT

Spill over to other scopes ???.....

48

500,000 procedures annually

>1000 use locations (potential placements)

GO TO MARKET STRATEGY

49

Channel Strategy

What Makes a Good Partner(s)?

Global in scope / leading regional players

Hungry: They commit their time and resources

Capable: Direct sales and service

Bundle: The ability to create “Sterilization Rooms”

STERIZONE® VP4 Sterilizer fills a “GAP” in their product portfolio: • Bolt-on product acquisition • Speed to market opportunity

50

Getinge Infection Control

• UK • Germany • France • Spain • Sweden • US and Canada • Turkey • Poland • Italy • Australia • Korea • China • Hong Kong / Taiwan / Macau • Czech Republic

51

Sales and Service Support • Getinge Infection Control

Associates: 3,089 Revenue: SEK 5,4 billion = USD 0.650 M Global Headquarters: Getinge, Sweden Sales Companies: 36 Manufacturing Locations: 10 Year Founded: 1904

52

Compatibility 53

Case Medical, Inc.® Instrument Trays Demonstrate Enhanced Performance when used in TSO3's Superior Low-Temperature STERIZONE® Sterilization System Québec City, March 23, 2015

Instrument Trays Made of Solvay's Radel® PPSU Show Strong Compatibility with TSO3's Low-Temperature Sterilization System ANAHEIM, California; Québec (Canada), February 11, 2015

Medical Instruments Category Battery Bipolar cord Bipolar forceps Bridge Camera Defibrillator paddles and handles Doppler probe Electrocautery instrument Electrode Electrophysiology cable Electrosurgical cable Fiberoptic light cable ENT flexible endoscope Flexible bronchoscope Flexible cystoscope Flexible hysteroscope Flexible nephroscope Flexible ureteroscope Forceps Laryngoscope blade High frequency cable Lacrimal probe Laser fiber Lighted retractor Ophthalmic surgical instrument (without channel) Resectoscope and resectoscope sheath Rigid endoscope (without channel) Rigid hysteroscope Scalpel handle Semi-rigid and rigid endoscope Speculum Stopcock Temperature probe Thoracoscope Trocar and trocar sheath

Short Term Efforts

TSO3 will IMMEDIATELY…

Support initial sales and service support agreement (Getinge)

• Sales training /Service Training • Quote Support System • Collaborative Marketing Programs

Initiate Group Purchasing /Integrated delivery networks (IDN) affiliations (USA)

Build inventory to match visible short term opportunities

Accelerate MDM/OEM endorsements for their IFU’s

54

In summary

FDA – Got it Financing – Did it Sales and Marketing – Started it Production – Building it Ozone Only Sterilizer – Discontinued it CRE – Not afraid of it Past – Remember it

Future – Looking forward to it

Success… – Counting on it!

55

May 6, 2015

Annual and Special Meeting of the Shareholders

THANK YOU

© TSO3 Inc., 2015 All rights reserved for all countries. No part of this publication may be reproduced

or translated in any form or by any means, without the prior written permission of TSO3 Inc.

- STERIZONE® are registered trademarks of TSO3 Inc.

U.S. Pat. No. 6,589,479 / 7,582,257 / 7,588,720 / 7,608,217 US pat. Applications No. 12/893,742; 13/779,132; 13/779,193; 13/780,464; 13/779,168; 13/779,200; 13/780,656

Corresponding patents granted or pending in other countries Other patents pending

57